Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer

Published:2023-11 Issue: Volume:Volume 16 Page:1015-1020
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Huang Yan^ORCID,Dai Shuang,Yin Wenlian,Luo Feng,Li Yan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference30 articles.

1. WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2021.

2. Small Cell Lung Carcinoma (SCLC)

3. Combined small-cell lung carcinoma

4. National Comprehensive Cancer Network. Small Cell Lung Cancer (version 3.2023). Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed November 27, 2023.

5. RETfusion gene: Translation to personalized lung cancer therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a novel high-performance liquid chromatography (HPLC) method for the detection of related substances of pralsetinib, a new anti-lung cancer drug;Frontiers in Chemistry;2024-08-21

2. Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4^th-line therapy with anlotinib: A case report;World Journal of Clinical Cases;2024-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP